The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide

This is a generated summary. It shows the 9 most-liked posts from a topic of 78, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
W
WoodhouseTL2Member15 Dec 2024#7
cohort_notes, post #3: Picking up post #2: that is the part I would want checked first. The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument from glycaemic control, which is why it mattered beyond its own numbers. Go to post

Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.

33 likes in reply to #3 19mo
ZV
z.vogelTL2 Moderator Solution16 Dec 2024#8
gradient_file, post #5: The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and should be called one. Go to post

I read post #6 twice before replying, because I had assumed the opposite.

The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.

7 likes in reply to #5 19mo
AD
ambient_draftTL3Regular21 Dec 2024#23
r.weiss, post #15: I read post #13 twice before replying, because I had assumed the opposite. Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound. Go to post

post #22 answers the question as asked. The question underneath it is different.

The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument from glycaemic control, which is why it mattered beyond its own numbers.

31 likes in reply to #15 19mo
HH
h.hutchingsTL1Member22 Dec 2024#27

post #26 is right about the mechanism and I think understates the practical bit.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

23 likes 19mo
I
IMainwaringTL3Regular27 Dec 2024#45

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

26 likes 19mo
HB
h.bhattacharyaTL2 Moderator29 Dec 2024#53

Worth separating two things that post #49 runs together.

The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.

24 likes 19mo
HM
h.mbekiTL2 Moderator30 Dec 2024#60

This follows post #57 rather than contradicting it.

On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.

25 likes 19mo
BV
bias_varianceTL4Biostatistician1 Jan 2025#67
h.mbeki, post #60: This follows post #57 rather than contradicting it. On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome. Go to post

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

24 likes in reply to #60 19mo
GV
g.valckenaereTL3Regular2 Jan 2025#71

Worth separating two things that post #67 runs together.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

28 likes 19mo

Read the full topic (78 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset
Asking directly, because I could not find a straight answer: What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset Session topic: SURMOUNT-1 ( N Engl J Med ,…
VBELIGRAC+112 130 2.2k 16mo
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold?
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N…
NSZSKRSIUC+58 62 49k 20mo
Semaglutide and alcohol: what is actually documented
Posting this under the heading it deserves: Semaglutide and alcohol: what is actually documented Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of a claim I do…
SFNNRGCSAZ+14 18 10k 2d
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile
Posting this under the heading it deserves: Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Everything below is what sits behind that. I have seen SCALE ( N Engl J Med…
DEIBHMMMCN+115 122 2.6k 1d
The C-cell question: rodent findings and their human context
Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of a…
SGSRSTSLFR+41 45 24k 12mo

Related topics — sharing the tags effect size, type 2 diabetes, randomised trial

TopicParticipantsRepliesViewsActivity
Revisiting: What pooling buys you and what it destroys
On the subject in the title: Revisiting: What pooling buys you and what it destroys Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…
JWZAEFIGGF+97 107 4k 19h
Journal club: STEP 3 and the intensive behavioural therapy floor
Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with STEP 4 (…
LSDOJFPWCL+6 10 13k 28d
Preprint servers and what screening they do
Preprint servers and what screening they do — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
BTSRDNMRL+95 106 5.6k 4mo
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…
AWFLAWCFZL+81 90 54k 9mo
Second pass at: Regression to the mean in progress reports
Second pass at: Regression to the mean in progress reports Writing it up because I had to work it out twice and would rather nobody else did. Comparing SUSTAIN 6 ( N Engl J Med , 2016) with STEP 4 ( JAMA ,…
SGCKIAMDM+71 75 4k 17mo